About 6 results found for searched term "Deruxtecan" (0.059 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M10396 | Deruxtecan | Drug-Linker Conjugates for ADC |
| Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402. | ||
| M24828 | Trastuzumab deruxtecan | Drug-Linker Conjugates for ADC |
| DS-8201; DS-8201a | ||
| Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, and a topoisomerase I inhibitor. Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer. | ||
| M25010 | Patritumab deruxtecan | Drug-Linker Conjugates for ADC |
| HER3-DXd; U3-1287; U3-1402 | ||
| Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity. | ||
| M40765 | Datopotamab deruxtecan | Others |
| Dato-DXd | ||
| Datopotamab deruxtecan is an antibody-coupled drug (ADC) consisting of a humanized, monoclonal antibody targeting human trophoblast cell surface glycoprotein antigen 2 (Trop2) conjugated to an innovative DNA topoisomerase I inhibitor (DXd) for use in studies related to non-small cell lung cancer (NSCLC). | ||
| M49457 | Ifinatamab deruxtecan | Others |
| DS-7300 | ||
| Ifinatamab deruxtecan is an antibody-drug coupling (ADC) targeting B7-H3 for studies related to small cell lung cancer. | ||
| M49458 | Raludotatug deruxtecan | Others |
| Raludotatug deruxtecan is a potential first-in-class antibody-drug coupling (ADC) targeting CDH6 for studies related to ovarian cancer. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
